Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.
Frontier Biotechnologies is seeking to enroll roughly 1,200 hospitalized COVID patients in an international Phase II/III clinical trial to evaluate its bofutrelvir (FB2001) in competition with Gilead’s Veklury.
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.
Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.
A preliminary analysis of Russian Phase III results for azvudine, China's first home-grown antiviral for COVID-19, shows it reached two primary endpoints, but a separate Chinese study produced mixed results.
Some products are still going strong, while others that once generated blockbuster revenues have faded away, as companies develop next-generation antivirals and vaccines.
Roche’s stock price has underperformed in the last nine months in spite of a natural hedge on the strong US dollar that has troubled most other profitable pharma companies. Has Roche become a value stock?
Preparing for the eventual transition to an open commercial market for COVID-19 vaccines and treatments, Pfizer restructured its commercial team to incorporate the franchises.
The company announced data showing the two-antibody drug had strong activity against Omicron BA.4, BA.5 and BA.2.12.1, but on the US market it would compete against oral drugs.
Founder CEO Sanjay Singh tells Scrip about Gennova Biopharma's preliminary talks with investors looking to grab a piece of the action post approval of its mRNA vaccine against COVID-19. As the company considers use of the technology in making vaccines against cancer and infectious diseases, it will also expand manufacturing
Dr Gilly Regev, CEO of the anti-infectives-focused firm, SaNOtize Research & Development Corp, remains confident of the effectiveness of the firm’s nitric oxide nasal spray against evolving variants of SARS-CoV-2 and expects to progress plans for a “prevention” trial in the US.
In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.
CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.
Rather than terminating a deal for the French biotech's VLA2001 vaccine, the European Commission has put in a tiny order of 1.25 million doses which could bring the curtain down on Valneva's COVID-19 programs.
Xocova’s emergency approval stymied by uncertainties over efficacy and other characteristics that could effectively limit its use, prompting decision to await Phase III data later this year.
Serum Institute will supply initial doses of NVX-CoV2373 in the US, but late approvals have meant Novavax's vaccine is facing weak demand and surplus stocks in other parts of the world. Meanwhile, Serum has also secured a nod in India for the first indigenously-developed HPV vaccine, also the fifth globally.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.